State Drug Price
Transparency Reporting

November 16th, 2021

11:00 AM – 12:00 PM EST

What to know before the launch of your first product

Drug prices within the U.S. continue to be a point of discussion with consumers, lawmakers and professionals throughout the healthcare industry. As of mid-2021, 21 states have enacted price transparency reporting requirement laws for pharmaceutical manufacturers, and with more states continuing to propose additional laws and regulations, the need to analyze and understand reporting obligations has never been greater. This is especially true for emerging pharmaceutical and biotech companies traversing the murky waters of varying reporting requirements when launching their first product.

Join KENX and Baker Tilly for an informative presentation about state drug price transparency reporting requirements for life sciences companies that are about to launch their first product. This webinar will cover:

  • The past, present and future state of state drug price transparency reporting
  • An understanding of what requirements emerging life sciences companies should be aware of before the launch of a new product
  • A high-level overview of select state price transparency requirements
  • Challenges and strategies to consider when navigating proprietary information, potential penalties and labor intensiveness of compliance

Who should attend?

  • C-Suite, legal, regulatory affairs, medical affairs, quality and safety, internal audit, and compliance and monitoring professionals at emerging and established life sciences companies



Ashley Jones

JD, Consultant, Baker Tilly

Ashley Jones is a legal consultant in the Baker Tilly Life Sciences practice group. Jones graduated from law school with a concentration in health law. While in law school she worked at multiple pharmaceutical companies, a health care insurer and a technology start-up focused on biometrics. Prior to law school, she completed her master’s degree and worked in the field of aging focused both on public policy work and direct consumer advocacy.

Erica Petersohn

Senior Manager, Baker Tilly

Erica Petersohn has more than 25 years of experience working for life sciences clients of varying sizes, brand and generic product mixes and contracting strategy models focused on the government segment. She started her career working in the Medicaid area and FSS contracting at and moved onto a pharmaceutical company where she focused on FSS contracting. She specializes in government pricing modeling and forecasting for FSS contracting negotiations and completed six FSS negotiations while in industry.